Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes
AssigneeThe Trustees of Princeton University
InventorsArnold J. Levine, Cathy A. Finlay, Carlos Cordon-Cardo
Life of this patent
Estimating the term…
Abstract
The invention provides a method of diagnosing cancer by determining the expression level or gene amplification of p53 and dm2, whereby an elevated level of either p53 or dm2 or both p53 and dm2 indicates a cancer diagnosis. Furthermore, the invention provides a method of predicting the progress of cancer by determining the expression level or gene amplification of p53 and dm2, whereby an elevated level of either p53 or dm2 or both p53 and dm2 indicated a poor prognosis.
Claims34
A method of assessing a subject's cancer prognosis, the method comprising:
- (a) obtaining a biological sample from the subject,
- (b) determining whether the level of either p53 or dm2 in the sample is abnormally elevated;
- and
- (c) classifying a biological sample into one of three groups, the first group comprises no abnormal elevation of either the level of p53 or dm2, the second group comprises abnormal elevation of the level of p53 and no abnormal elevation of the level of dm2 or abnormal elevation of the level of dm2 and no abnormal elevation of the level of p53, and the third group comprises abnormal elevation of the level of both p53 and dm2, whereby the first group indicates the best prognosis, the second group indicates an intermediate prognosis, and the third group indicates the worst prognosis.
A method of detecting in a biological sample cancer cells or cells at risk of becoming cancerous or pre-cancerous, wherein th cells contain at least one normal p53 allele, the method comprising determining whether the level of dm2 in the biological sample is abnormally elevated in comparison with the level of dm2 expression in normal biological samples, whereby an abnormally elevated level of dm2in the assayed biological sample indicates cancer cells or cells at risk of becoming cancerous or pre-cancerous.
A method of diagnosing cancer by determining the level of p53 and dm2 in a biological sample, whereby an elevated level of either p53 or dm2 or both p53 and dm2 indicates a cancer diagnosis.
A method of predicting the progress of cancer by determining the level of p53 and dm2 in a biological sample, whereby an elevated level of either p53 or dm2 or both p53 and dm2 indicates a poor prognosis.
The monoclonal antibody produced by hybridoma 3G5, deposited under ATCC Accession No. HB 11182.
The monoclonal antibody produced by hybridoma 4B11, deposited under ATCC Accession No. HB 11183.
The monoclonal antibody produced by hybridoma 2A10, deposited under ATCC Accession No. HB 11184.
The monoclonal antibody produced by hybridoma 2A9, deposited under ATCC Accession No. HB 11185.
The monoclonal antibody produced by hybridoma 4B2, deposited under ATCC Accession No. HB 11186.
A monoclonal antibody that recognizes the same epitope or epitopes as those recognized by a monoclonal antibody produced by a hybridoma selected from the group consisting of hybridoma 3G5, deposited under ATCC Accession No. HB 11182;
- hybridoma 4B11, deposited under ATCC Accession No. HB 11183;
- hybridoma 2A10, deposited under ATCC Accession No. HB 11184;
- hybridoma 2A9, deposited under ATCC Accession No. HB 11185;
- and hybridoma 4B2, deposited under ATCC Accession No. HB 11186.
A monoclonal antibody that competes with a monoclonal antibody produced by a hybridoma selected from the group consisting of hybridoma 3G5, deposited under ATCC Accession No. HB 11182;
- hybridoma 4B11, deposited under ATCC Accession No. HB 11183;
- hybridoma 2A10, deposited under ATCC Accession No. HB 11184;
- hybridoma 2A9, deposited under ATCC Accession N. HB 11185;
- and hybridoma 4B2, deposited under ATCC Accession No. HB11186 for binding to the same epitope or epitopes as those recognized by a monoclonal antibody produced by any of these hybridomas.
A monoclonal antibody according to claim 73 that blocks between 50-100% of the epitope or epitopes recognized by the monoclonal antibody produced by a hybridoma selected from the group consisting of hybridoma 3G5, deposited under ATCC Accession No. HB 11182;
- hybridoma 4B11, deposited under ATCC Accession No. HB 11183;
- hybridoma 2A10, deposited under ATCC Accession No. HB 11184;
- hybridoma 2A9, deposited under ATCC Accession No. HB 11185;
- and hybridoma 4B2, deposited under ATCC Accession No. HB 11186.
A hybridoma selected from the group consisting of hybridoma 3G5, deposited under ATCC Accession No. HB 11182;
- hybridoma 4B11, deposited under ATCC Accession No. HB 11183;
- hybridoma 2A10, deposited under ATCC Accession No. HB 11184;
- hybridoma 2A9, deposited under ATCC Accession No. HB 11185;
- and hybridoma 4B2, deposited under ATCC Accession No. HB 11186.
A diagnostic kit comprising:
- (a) a container comprising an anti-p53 antibody that recognizes a p53 protein;
- and
- (b) a container comprising an anti-dm2 antibody that recognizes a dm2 protein.
Dependencies are inferred from the claim text.